This is an old revision of this page, as edited by 58.111.66.244 (talk) at 13:31, 18 April 2011. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 13:31, 18 April 2011 by 58.111.66.244 (talk)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundCombination of | |
---|---|
Amlodipine | Calcium channel blocker |
Atorvastatin | Statin |
Clinical data | |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
3D model (JSmol) | |
SMILES
| |
InChI
|
The drug combination atorvastatin/amlodipine (trade names Caduet in the US and Australia, and Envacar elsewhere) is a medication approved by the Food and Drug Administration (FDA) for the treatment of high cholesterol and high blood pressure. It is a fixed dose combination drug containing the calcium channel blocker amlodipine and the statin atorvastatin. It is being marketed by the pharmaceutical company Pfizer.
References
- "CADUET (amlodipine besylate/atorvastatin calcium) Tablets" (PDF). NDA 21-540/S-009. United States Food and Drug Administration. 2010. Retrieved 2010-09-25.
{{cite web}}
: Unknown parameter|month=
ignored (help)
External links
- Manufacturer's site (caduet.com)
This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it. |